Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.

Nature reviews. Clinical oncology - 1 Oct 2018

Cabel Luc, Proudhon Charlotte, Romano Emanuela, Girard Nicolas, Lantz Olivier, Stern Marc-Henri, Pierga Jean-Yves, Bidard François-Clément

Abstract excerpt

Considerable interest surrounds the use of immune-checkpoint inhibitors in patients with solid tumours following the demonstration of the impressive clinical efficacy of anti-programmed cell death protein 1 and anti-programmed cell death 1 ligand 1 antibodies in several tumour types. However, the emergence of unexpected tumour response patterns, such as pseudoprogression or hyperprogression, might complicate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Immunotherapy

Share to Mutation

Share to Neoplasms

Source

Identifiers

PMID: 30050094
DOI: 10.1038/s41571-018-0074-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.PMID 30050094Read ↗

Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With ImmunotherapySemantic proximity Read ↗

The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancerSemantic proximity Read ↗

The translational potential of circulating tumour DNA in oncology.Semantic proximity Read ↗

Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challengesSemantic proximity Read ↗

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.Semantic proximity Read ↗

Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of CancerSemantic proximity Read ↗

Circulating tumour DNA in B‐cell lymphomas: current state and future prospectsSemantic proximity Read ↗

Circulating-tumor DNA as an early detection and diagnostic tool.Semantic proximity Read ↗

Circulating tumour DNA as a cancer biomarker.Semantic proximity Read ↗

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.Semantic proximity Read ↗

Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response.Semantic proximity Read ↗

Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.